BrainStorm Cell Therapeutics (BrainStorm) has entered into an agreement with Protein Production Services (PPS) in order to start Good Manufacturing Practice (cGMP) production of its stem cell therapeutic
The Medicines Company has reported data for HORIZONS-AMI Trial, which evaluated Angiomax for one year. The trial showed that patients who had suffered the most severe form of
A study conducted by US-based Merck, demonstrated that in 22,000 patients, nearly three-quarters of patients taking statins still had at least one lipid abnormality. The results from the
Delcath Systems has reported that the FDA has granted orphan drug designation for doxorubicin for the treatment of hepatocellular carcinoma (HCC). Doxorubicin is a common chemotherapy agent shown
To support this new organizational structure the leadership changes are as follows: Spinal and Biologics, Neuromodulation, Diabetes, and Surgical Technologies Group Chris O’Connell has been promoted to the
BioSyent has signed an exclusive product development, supply and distribution agreement with a new partner for a new product under its Hospital Products Division. Reportedly, the product will
Celladon and Momentum Research have reported the completion of enrollment of the phase 2 double-blind portion of the Calcium Up-regulation by Percutaneous Administration of Gene Therapy in Cardiac
Sinovac has reported that Sinovac’s H1N1 vaccine has passed the experts evaluation by State Food and Drug Administration (SFDA). The vaccine is expected to obtain the production license
AstraZeneca has announced results from the phase III head to head trial, PLATO, which demonstrate that ticagrelor (BRILINTA) has achieved greater efficacy in the primary endpoint, reduction of
Sanofi-aventis’ anti-Xa intravenous anticoagulant otamixaban has reduced by 27 to 42% the odds of the composite primary endpoint of death, myocardial infarction, urgent revascularization or rescue GPIIb/IIIa use
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.